Search
Now showing items 1-6 of 6
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
(BMC Health Services Research, 2009-01-09)
Background Lower-income countries face severe health worker shortages. Recent evidence suggests that this problem can be mitigated by task-shifting—delegation of aspects of health care to less specialized health workers. ...
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
(Oxford University Press, 2012)
Objectives: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz ...
Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis
(Public Library of Science, 2012-06)
Background: In Uganda, isoniazid plus ethambutol is used for 6 months (6HE) during the continuation treatment phase of new tuberculosis (TB) cases. However, the World Health Organization (WHO) recommends using isoniazid ...
Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
(Dove Medical Press, 2009)
Artemether–lumefantrine is one of the artemisisnin-based combination therapies recommended for treatment of uncomplicated falciparum malaria. The drug combination is highly efficacious against sensitive and multidrug ...
Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
(Dove Medical Press, 2009)
Artemether–lumefantrine is one of the artemisisnin-based combination therapies recommended for treatment of uncomplicated falciparum malaria. The drug combination is highly efficacious against sensitive and multidrug ...
“You would not be in a hurry to go back home”: Patients’ willingness to participate in HIV/AIDS clinical trials at a clinical and research facility in Kampala, Uganda
(BMC, 2020)
Background: Few studies have examined factors associated with willingness of people living with HIV (PLHIV) to
participate in HIV treatment clinical trials in Sub-Saharan Africa. We assessed the factors associated with ...